A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease
The purpose of this study is to evaluate the safety and efficacy of a study drug that targets an abnormal protein in the brain found in people with Alzheimer's Disease (AD).
Trial Summary
Key Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Participants must have gradual and progressive change in memory function for >6 months
Participants must have a family member or close friend who is with participant at least 10 hours per week and can attend study appointments
Participants Must Not:
Participants must not have significant neurological disease affecting the nervous system, other than AD, that affects cognition or may affect completion of the study
Participants must not have serious or unstable illness that could interfere with the analysis of the study or have a life expectancy <24 months
Participants must not have history of cancer within the last 5 years with the exception of certain types of skin, cervical, prostate, and other cancers that are not likely to recur or spread
Participants must not have serious risk for suicide
Participants must not have history of drug or alcohol use disorder within the last 2 years
Participants must not have multiple severe drug allergies
Participants must not have HIV, hepatitis B or hepatitis C
Lilly Trial Alerts
You will complete the questionnaire on another website.YesNo